Adam Nicolson became the first person in Scotland to receive CAR-T cell therapy for myeloma after exhausting all other options. Now in remission, his case is driving new research into the therapy’s potential for autoimmune diseases.
Holtec Nuclear abruptly postponed its $825 million IPO while Nscale filed for a potential $2 billion offering and Electra Therapeutics suffered a rare biotech IPO drop.
A surge of more than 180 companies is driving over 200 CAR-T therapies through the clinical pipeline, with new strategies aiming to overcome resistance and expand beyond cancer.
North Carolina’s life sciences sector is taking a measured approach to growth, favoring smaller, risk-managed deals and targeted expansions, while a few major players make billion-dollar commitments.
Mayo Clinic researchers have shown that drugs used for advanced thyroid cancer can make aggressive tumors visible again to CAR-T cells, improving tumor control and survival in preclinical studies.
Bristol Myers Squibb has stopped development of Orum Therapeutics' CD33-targeted AML drug, erasing USD 80 million in milestone payments and leaving only one approved agent in the clinical-stage DAC field.
A single in vivo CAR-T injection shows early promise for multiple sclerosis, while new research connects ADHD to digestive issues and looks at how wholegrain diets affect heart risk factors.
LSUA has broken new ground with the first accredited 90 credit hour accelerated bachelor's degrees in bioinformatics and information technology, offering students a faster and more focused route into high-demand STEM fields.
Dualitas Therapeutics has signed a $36.5 million upfront agreement with Roche for access to its DualScreen Bispecific Discovery Engine, with total payments that could reach $1 billion.
Arovella Therapeutics has received FDA clearance to begin Phase 1 clinical testing of its allogeneic cell therapy ALA-101 targeting CD19-positive blood cancers.
Certara is betting that catching data standard problems at the source can save clinical trial sponsors months of costly remediation and regulatory headaches.
SK Biopharmaceuticals has signed a licensing and equity agreement with 1ST Biotherapeutics, gaining exclusive global rights to a preclinical Parkinson's disease candidate with a dual-inhibition mechanism.
Florida citrus growers are betting on gene edited rootstock to fight a bacterial disease that has decimated their groves and production.
